Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Jiafeng Liu, Tianxiao Wang, Wenxin Zhang, Yuxin Huang, Xinhai Wang, Qunyi Li
BACKGROUND: The cancers of the digestive tract, including colorectal cancer (CRC), gastric cancer (GC) and Esophageal cancer (ESCA), are part of the most common cancers as well as one of the most important leading causes of cancer death worldwide. SUMMARY: Despite the emergence of immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1/PD-L1) in the past decade, offering renewed optimism in cancer treatment, only a fraction of patients derive benefit from these therapies...
April 18, 2024: Oncology Research and Treatment
#2
Andrea Valera-Barrero, Jorge Madera-Fernández, Vicente González-Quintanilla, María José Sedano-Tous, Francisco Martínez Dubarbie
INTRODUCTION: Breast cancer in males is a very rare entity, and survival is mainly influenced by the stage at diagnosis. The lack of early detection tools in men results in a diagnostic delay of about 5-10 years and a higher percentage of metastatic disease at diagnosis. However, the characteristics of head metastases are not well defined. CASE REPORTS: We present two cases of male breast cancer with metastases affecting cranial nervous structures and we provide imaging and histologic data...
April 18, 2024: Oncology Research and Treatment
#3
JOURNAL ARTICLE
Gul Sema Yıldıran Keskin, Ismail Ertürk, Musa Baris Aykan, Ramazan Acar, Aysegul Dumludag, Alper Topal, Caglar Koseoglu, Omer Faruk Kuzu, Ece Ornek, Nuri Karadurmus
PURPOSE: The optimal management of relapsed/refractory germ cell tumors remains unsettled. In this study, we aimed to evaluate the efficacy of high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) as salvage therapy in patients who progressed after at least one line of cisplatin-based chemotherapy. METHODS: We retrospectively reported the results of 133 patients who underwent HDCT and ASCT as salvage therapy from 2016 to 2021. Patients received 3 cycles of paclitaxel, ifosfomide and cisplatin (TIP) regimen as induction and 1 cycle of carboplatin 700 mg/m2 on days 1 to 3 plus etoposide 750 mg/m2 on days 1 to 3, followed by ASCT...
April 5, 2024: Oncology Research and Treatment
#4
JOURNAL ARTICLE
Marnix H Geukes Foppen, Maartje W Rohaan, Jessica S W Borgers, Daisy Philips, Florry Vyth-Dreese, Jos H Beijnen, Bastiaan Nuijen, Joost H van den Berg, John B A G Haanen
INTRODUCTION: Naked DNA vaccination could be a powerful and safe strategy to mount antigen-specific cellular immunity. We designed a phase I clinical trial to investigate the toxicity of naked DNA vaccines encoding CD8+ T-cell epitope from tumor-associated antigen MART-1 in patients with advanced melanoma. METHODS: This dose escalating phase Ia clinical trial investigates the toxicity and immunological response upon naked DNA vaccines encoding a CD8+ T-cell epitope from the tumor-associated antigen MART-1, genetically linked to the gene encoding domain 1 of subunit-tetanus toxin fragment C in patients with advanced melanoma (inoperable stage IIIC-IV, AJCC 7th edition)...
April 5, 2024: Oncology Research and Treatment
#5
LETTER
Marcel Kemper, Puyan Soltani Germy, Fabian Acker, Jingting Luan, Frank Griesinger, Amanda Tufman, Cornelia Kropf-Sanchen, Tobias R Overbeck, Annalen Bleckmann, Miriam Blasi
No abstract text is available yet for this article.
April 4, 2024: Oncology Research and Treatment
#6
JOURNAL ARTICLE
Nargiz Majidova, Murat Sari, Fatma Akdag Kahvecıglu, Erkan Ozcan, Mutıanur Ozkorkmaz Akdag, Akıf Dogan, Sedat Yıldırım, Sermın Dınc Sonusen, Emıl Yunusov, Alper Yasar, Abdussamet Celebi, Nadıye Sever, Erkam Kocaaslan, Pınar Erel, Yesım Agyol, Ali Kaan Guren, Rukiye Arikan, Selver Işık, Ozlem Balvan, Caglayan Geredeli, Kazım Uygun, Ilhan Hacıbekiroğlu, Osman Kostek, İbrahim Vedat Bayoğlu
INTRODUCTION: Nasopharyngeal carcinoma (NPC) accounts for 0.01% of all carcinomas, and 70% of patients have locally advanced disease with a poor prognosis. The mainstay therapy is chemoradiotherapy (CRT), and concurrent administration of platinum-based agents and irradiation provides high local control rates. However, induction (neoadjuvant) chemotherapy (ICT) prior to chemoradiotherapy is recommended for large tumors with a high tumor burden at category 1 level. For induction chemotherapy, platinum-based doublet or triplet combination regimens are recommended...
April 2, 2024: Oncology Research and Treatment
#7
JOURNAL ARTICLE
Kathrin Heinrich, Volker Heinemann, Sebastian Stintzing, Lothar Müller, Thomas J Ettrich, Petra Buechner-Steudel, Michael Geißler, Jörg Trojan, Nicolas Moosmann, Gunnar Folprecht, Johannes Schmidt, Stephan Kanzler, Frank Kullmann, Jean-Charles Moulin, Jens Werner, Martin K Angele, Victoria Probst, Swantje Held, Christoph Schulz, Myrto Boukovala
INTRODUCTION: S-1 has been shown to be an effective adjuvant treatment option for East Asian patients who underwent gastrectomy for stage II/III gastric cancer. We conducted a phase I/II study to evaluate the feasibility, tolerability and efficacy of administering S-1 in the adjuvant setting after R0-resection of adenocarcinoma of the stomach and esophagogastric junction (EGJ) in Caucasian patients. METHODS: In this single-cohort, open-label, phase I/II trial, we enrolled patients with locally advanced adenocarcinoma of the stomach or EGJ having undergone R0-resection with or without neoadjuvant treatment...
April 2, 2024: Oncology Research and Treatment
#8
LETTER
Fabian Acker, Jingting Luan, Puyan Soltani Germy, Marcel Kemper, Miriam Blasi, Frank Griesinger, Amanda Tufman, Annalen Bleckmann, Cornelia Kropf-Sanchen, Tobias R Overbeck
No abstract text is available yet for this article.
March 25, 2024: Oncology Research and Treatment
#9
JOURNAL ARTICLE
Norbert Marschner, Wolfgang Knauf
INTRODUCTION: Survival data reported by randomised controlled trials are collected in a highly selected patient population and can thus only be transferred to a limited extent to real-world patients: the patients in routine care are mostly older, present with more comorbidities and a worse general state of health. This so-called efficacy-effectiveness gap typically results in inferior survival data in routine healthcare. METHODS: Six prospective clinical tumour registries recruited a total of 11,679 patients receiving systemic therapy in haemato-oncological practices in Germany between 2006 and 2020...
March 15, 2024: Oncology Research and Treatment
#10
JOURNAL ARTICLE
Jieshi Zhang, Yuxiao Lin, Jiong Zhou, Ruixuan Geng, Zhibo Zheng, Chao Guo, Xiaojun Ma, Shanqing Li
INTRODUCTION: Lymphadenectomy is a cornerstone in the surgical management of resectable primary lung cancer. However, its prognostic significance in early-stage metachronous second primary lung cancer(MSPLC) remains poorly understood. This retrospective study aims to evaluate the prognostic impact of lymphadenectomy in these patients using data from the Surveillance, Epidemiology, and End Results (SEER) Database. METHODS: A retrospective cohort study was conducted using data from the SEER Database for patients surgically treated for stage I MSPLC between 2004 and 2015...
March 15, 2024: Oncology Research and Treatment
#11
Celine Lugnier, Sabine Sommerlatte, Ulrike Attenberger, Ambros J Beer, Martin Bentz, Stefan R Benz, Thomas Birkner, Jens Büntzel, Matthias Ebert, Peter Fasching, Wolfgang Fischbach, Emmanouil Fokas, Birgit Fricke, Helene Hense, Erich Grohmann, Ralf-Dieter Hofheinz, Dietrich Hüppe, Stefan Huster, Patrick Jahn, Monika Klinkhammer-Schalke, Wolfgang Knauf, Anna-Lena Kraeft, Bernd Oliver Maier, Georg Marckmann, Günter Niegisch, Lutz Otto, Uwe Pelzer, Pompiliu Piso, Henning Rosenau, Jochen Schmitt, Olaf Schoffer, Jalid Sehouli, Andrea Tannapfel, Ulrich Wedding, Simone Wesselmann, Eva C Winkler, Tanja Zimmermann, Bernhard Wörmann, Anke Reinacher-Schick, Jan Schildmann
In the context of the COVID-19 pandemic, there has been a scarcity of resources with various effects on the care of cancer patients. This paper provides an English summary of a German guideline on prioritization and resource allocation for colorectal and pancreatic cancer in the context of the pandemic. Based on a selective literature review as well as empirical and ethical analyses, the research team of the CancerCOVID Consortium drafted recommendations for prioritizing diagnostic and treatment measures for both entities...
March 14, 2024: Oncology Research and Treatment
#12
LETTER
Magdalena K Scheck, Ira Ekmekciu, Greta Sommerhäuser, Christian Heise, Ilektra Antonia Mavroeidi, Volker Kunzmann, Henning Wege, Anke Reinacher-Schick, Ralf-Dieter Hofheinz, Thorsten Oliver Götze, Sylvie Lorenzen, Alexander Nieto
No abstract text is available yet for this article.
March 13, 2024: Oncology Research and Treatment
#13
JOURNAL ARTICLE
Andreas Katsimpris, Antonios G Antoniadis, Nick Dessypris, Konstantinos Karampinos, Helen J Gogas, Eleni Th Petridou
INTRODUCTION: It has been postulated that nutrition may influence the risk for cutaneous melanoma (CM); therefore, we aimed to assess the associations of food groups and individual nutrient intakes with CM in a Greek population. METHODS: In this case-control study, 151 patients with histologically confirmed CM, newly diagnosed and treated in the Oncology Department of the 'Laikon' University Hospital (Athens, Greece), and 151 age- and sex-matched healthy individuals residing in the Athens metropolitan area, recruited among participants for routine health examinations were included...
March 12, 2024: Oncology Research and Treatment
#14
REVIEW
Oliver Rick, Alexandra Gerhardt, Georgia Schilling
BACKGROUND: Cancer-related cognitive dysfunction (CRCD) is a major functional disorder in patients with cancer. This central nervous dysfunction is found in up to 60 % of patients after tumour therapy, often significantly limits the quality of life and significantly impedes participation in working life. For this reason, diagnosis and treatment of CRCD is of central importance. This narrative review is intended to provide an overview and support for practical clinical care with regard to diagnostics and therapeutic options...
March 12, 2024: Oncology Research and Treatment
#15
JOURNAL ARTICLE
Marietta Lieb, Martina Madl, Martin Vogelhuber, Matthias W Beckmann, Yesim Erim
BACKGROUND: Self-help groups (SHGs) are an important cornerstone of the German health care system. Especially collaborations of SHGs with cancer centers enable active patient involvement in cancer care. We investigated the current situation and unmet needs of Bavarian SHGs in order to point out possible options of action. METHODS: We conducted a cross-sectional study with Bavarian psycho-oncological SHGs. Via E-Mail, an online survey was sent to 150 SHGs registered at the BZKF (Bavarian Cancer Research Center)...
March 8, 2024: Oncology Research and Treatment
#16
Leonid L Yavorkovsky
INTRODUCTION: The management of malignant spinal cord compression (mSCC) is a demanding task. The main challenges of mSCC include various manifestations and unpredictable outcomes with indiscriminate treatment recommendations. Because of attendant urgency with potentially devastating health consequences, the SCC is an emotionally disturbing experience whose management could take an impulsive rather than rational approach. The treatment strategy is particularly problematic when mSCC is caused by a malignant lymphoma with its protean attributes...
March 1, 2024: Oncology Research and Treatment
#17
LETTER
Ira Ekmekciu, Alexander Edward Nieto, Magdalena K Scheck, Christian Heise, Ilektra Antonia Mavroeidi, Volker Kunzmann, Thorsten Oliver Götze, Henning Wege, Anke Reinacher-Schick, Sylvie Lorenzen, Ralf-Dieter Hofheinz, Greta Sommerhäuser
No abstract text is available yet for this article.
March 1, 2024: Oncology Research and Treatment
#18
JOURNAL ARTICLE
Thomas Golombek, Nora Hegewald, Astrid Schnabel, Hansjakob Fries, Florian Lordick
INTRODUCTION: Early integration of palliative care and advance care planning (ACP) play an increasingly important role in the treatment of patients with advanced cancer. Advance directives (ADs) and patients' preferences regarding End-of-life (EoL) care are important aspects of ACP. In the outpatient setting, the prevalence of those documents and EoL care wishes are not well investigated and changes in the longitudinal course are poorly understood. METHODS: From June 2020 to August 2022, 67 outpatients with advanced solid tumors undergoing palliative cancer therapy were interviewed on the topic of ACP in a longitudinal course...
March 1, 2024: Oncology Research and Treatment
#19
LETTER
Maria Pouyiourou, Lea Elisabeth Reitnauer, Alexej Ballhausen, Annabel Helga Sophie Alig, Annalen Bleckmann, Christoph Benedikt Westphalen, Maximilian Kloft
No abstract text is available yet for this article.
February 28, 2024: Oncology Research and Treatment
#20
LETTER
Christian Heise, Alexander Edward Nieto, Magdalena K Scheck, Ira Ekmekciu, Greta Sommerhäuser, Anke Reinacher-Schick, Ralf-Dieter Hofheinz, Sylvie Lorenzen, Henning Wege, Volker Kunzmann, Thorsten Oliver Götze, Ilektra Antonia Mavroeidi
No abstract text is available yet for this article.
February 22, 2024: Oncology Research and Treatment
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
